"old Dogs with New Tricks": Exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets

Molecular BioSystems

Volumn 10, Issue 8, 2014, Pages 1998-2022

  Kang, Dongwei ^a   Song, Yu'Ning ^a   Chen, Wenmin ^a   Zhan, Peng ^a   Liu, Xinyong ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL RESISTANCE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84903780807     PISSN: 1742206X     EISSN: 17422051     Source Type: Journal    
DOI: 10.1039/c4mb00147h     Document Type: Review

References (137)

1. L. Menéndez-Arias Molecular basis of human immunodeficiency virus type 1 drug resistance: Overview and recent developments Antiviral Res. 2013 98 93 120
2. L. Menéndez-Arias Molecular basis of human immunodeficiency virus drug resistance: an update Antiviral Res. 2010 85 210 231
3. M. M. Zdanowicz The pharmacology of HIV drug resistance Am. J. Pharm. Educ. 2006 70 100
4. K. Das E. Arnold HIV-1 reverse transcriptase and antiviral drug resistance. Part 1 Curr. Opin. Virol. 2013 3 111 118
5. K. Das E. Arnold HIV-1 reverse transcriptase and antiviral drug resistance. Part 2 Curr. Opin. Virol. 2013 3 119 128
6. E. L. Asahchop M. A. Wainberg R. D. Sloan C. L. Tremblay Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors Antimicrob. Agents Chemother. 2012 56 5000 5008
7. F. Esposito A. Corona E. Tramontano HIV-1 reverse transcriptase still remains a new drug target: structure, function, classical inhibitors, and new inhibitors with innovative mechanisms of actions Mol. Biol. Int. 2012 2012 586401
8. R. A. Smith L. A. Loeb B. D. Preston Lethal mutagenesis of HIV Virus Res. 2005 107 215 228
9. L. A. Loeb J. I. Mullins Lethal mutagenesis of HIV by mutagenic ribonucleoside analogs AIDS Res. Hum. Retroviruses 2000 16 1 3
10. L. A. Loeb J. M. Essigmann F. Kazazi J. Zhang K. D. Rose J. I. Mullins Lethal mutagenesis of HIV with mutagenic nucleoside analogs Proc. Natl. Acad. Sci. U. S. A. 1999 96 1492 1497
11. M. J. Dapp C. L. Clouser S. Patterson L. M. Mansky 5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1 J. Virol. 2009 83 11950 11958
12. K. S. Harris W. Brabant S. Styrchak A. Gall R. Daifuku KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis Antiviral Res. 2005 67 1 9
13. Y. E. Safadi J. C. Paillart G. Laumond A. M. Aubertin A. Burger R. Marquet V. Vivet-Boudou 5-Modified-2′-dU and 2′-dC as mutagenic anti HIV-1 proliferation agents: synthesis and activity J. Med. Chem. 2010 53 1534 1545
14. M. D. Cullen W. C. Ho J. D. Bauman K. Das E. Arnold T. L. Hartman K. M. Watson R. W. Buckheit C. Pannecouque E. De Clercq M. Cushman Crystallographic study of a novel subnanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 reverse transcriptase J. Med. Chem. 2009 52 6467 6473
15. P. Zhan Z. Li X. Liu Cosalane and Its Analogues: A Unique Class of Anti-HIV Agents Mini-Rev. Med. Chem. 2010 10 966 976
16. K. Das J. D. Bauman A. S. Rim C. Dharia A. D. Clark Jr. M. J. Camarasa J. Balzarini E. Arnold Crystal structure of tert-butyldimethylsilyl- spiroaminooxathioledioxide-thymine (TSAO-T) complexed with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket J. Med. Chem. 2011 54 2727 2737
17. J. D. Pata W. G. Stirtan S. W. Goldstein T. A. Steitz Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors Proc. Natl. Acad. Sci. U. S. A. 2004 101 10548 10553
18. G. Maga M. Radi M. A. Gerard M. Botta E. Ennifar HIV-1 RT inhibitors with a novel mechanism of action: NNRTIs that compete with the nucleotide substrate Viruses 2010 2 880 899
19. G. Maga M. Radi S. Zanoli F. Manetti R. Cancio U. Hübscher S. Spadari C. Falciani M. Terrazas J. Vilarrasa M. Botta Discovery of non-nucleoside inhibitors of HIV-1 reverse transcriptase competing with the nucleotide substrate Angew. Chem., Int. Ed. 2007 46 1810 1813
20. M. Radi C. Falciani L. Contemori E. Petricci G. Maga A. Samuele S. Zanoli M. Terrazas M. Castria A. Togninelli J. A. Esté I. Clotet-Codina M. Armand-Ugón M. Botta A multidisciplinary approach for the identification of novel HIV-1 non-nucleoside reverse transcriptase inhibitors: S-DABOCs and DAVPs ChemMedChem 2008 3 573 593
21. S. Freisz G. Bec M. Radi P. Wolff E. Crespan L. Angeli P. Dumas G. Maga M. Botta E. Ennifar Crystal structure of HIV-1 reverse transcriptase bound to a non-nucleoside inhibitor with a novel mechanism of action Angew. Chem., Int. Ed. 2010 49 1805 1808
22. M. Radi, M. Botta, L. Angeli, P. Wolff, E. Crespan, L. Angeli, P. Dumas, G. Maga, M. Botta and E. Ennifar, Crystal structure of HIV-1 reverse transcriptase bound to a nucleotide-competitive reverse transcriptase inhibitor and it use for the design and identification of inhibitors, PCT Int. Appl., WO 2011073959 A2, 2011
23. Z. Zhang M. Walker W. Xu J. H. Shim J. L. Girardet R. K. Hamatake Z. Hong Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase Antimicrob. Agents Chemother. 2006 50 2772 2781
24. D. Jochmans J. Deval B. Kesteleyn H. Van Marck E. Bettens I. De Baere P. Dehertogh T. Ivens M. Van Ginderen B. Van Schoubroeck M. Ehteshami P. Wigerinck M. Götte K. Hertogs Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action J. Virol. 2006 80 12283 12292
25. O. Jegede A. Khodyakova M. Chernov J. Weber L. Menéndez-Arias A. Gudkov M. E. Quiñones-Mateu Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system Antiviral Res. 2011 91 94 98
26. M. Ehteshami M. Nijhuis J. A. Bernatchez C. J. Ablenas S. McCormick D. de Jong D. Jochmans M. Götte Formation of a Quaternary Complex of HIV-1 Reverse Transcriptase with a Nucleotide-competing Inhibitor and its ATP Enhancer J. Biol. Chem. 2013 288 17336 17346
27. M. Tremblay R. C. Bethell M. G. Cordingley P. Deroy J. Duan M. Duplessis P. J. Edwards A. M. Faucher T. Halmos C. A. James C. Kuhn J. É. Lacoste L. Lamorte S. R. Laplante E. Malenfant J. Minville L. Morency S. Morin D. Rajotte P. Salois B. Simoneau S. Tremblay C. F. Sturino Identification of benzofurano[3,2-d]pyrimidin-2-ones, a new series of HIV-1 nucleotide-competing reverse transcriptase inhibitors Bioorg. Med. Chem. Lett. 2013 23 2775 2780
28. C. A. James P. Deroy M. Duplessis P. J. Edwards T. Halmos J. Minville L. Morency S. Morin B. Simoneau M. Tremblay R. Bethell M. Cordingley J. Duan L. Lamorte A. Pelletier D. Rajotte P. Salois S. Tremblay C. F. Sturino Nucleotide competing reverse transcriptase inhibitors: Discovery of a series of non-basic benzofurano[3,2-d]pyrimidin-2-one derived inhibitors Bioorg. Med. Chem. Lett. 2013 23 2781 2786
29. D. Rajotte S. Tremblay A. Pelletier P. Salois L. Bourgon R. Coulombe S. Mason L. Lamorte C. Sturino R. Bethell Identification and characterization of a novel HIV-1 nucleotide competing RT inhibitor series Antimicrob. Agents Chemother. 2013 57 2712 2718
30. L. Z. Wang G. L. Kenyon K. A. Johnson Novel mechanism of inhibition of HIV-1 reverse transcriptase by a new non-nucleoside analog, KM-1 J. Biol. Chem. 2004 279 38424 38432
31. A. G. Skillman K. W. Maurer D. C. Roe M. J. Stauber D. Eargle T. J. Ewing A. Muscate E. Davioud-Charvet M. V. Medaglia R. J. Fisher E. Arnold H. Q. Gao R. Buckheit P. L. Boyer S. H. Hughes I. D. Kuntz G. L. Kenyon A novel mechanism for inhibition of HIV-1 reverse transcriptase Bioorg. Chem. 2002 30 443 458
32. S. Yamazaki L. Tan G. Mayer J. S. Hartig J. N. Song S. Reuter T. Restle S. D. Laufer D. Grohmann H. G. Kräusslich J. Bajorath M. Famulok Aptamer displacement identifies alternative small-molecule target sites that escape viral resistance Chem. Biol. 2007 14 804 812
33. A. Herschhorn I. Oz-Gleenberg A. Hizi Mechanism of inhibition of HIV-1 reverse transcriptase by the novel broad-range DNA polymerase inhibitor N-{2-[4-(aminosulfonyl) phenyl]ethyl}-2-(2-thienyl)acetamide Biochemistry 2008 47 490 502
34. F. Yu X. Liu P. Zhan E. De Clercq Recent advances in the research of HIV-1 RNase H inhibitors Mini-Rev. Med. Chem. 2008 8 1243 1251
35. L. Cao W. Song E. De Clercq P. Zhan X. Liu Recent progress in the research of small molecule HIV-1 RNase H inhibitors Curr. Med. Chem. 2014 21 1956 1967
36. E. Tramontano R. Di Santo HIV-1 RT-associated RNase H function inhibitors: recent advances in drug development Curr. Med. Chem. 2010 17 2837 2853
37. S. Chung D. M. Himmel J. K. Jiang K. Wojtak J. D. Bauman J. W. Rausch J. A. Wilson J. A. Beutler C. J. Thomas E. Arnold S. F. Le Grice Synthesis, activity, and structural analysis of novel α-hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H J. Med. Chem. 2011 54 4462 4473
38. S. R. Budihas I. Gorshkova S. Gaidamakov A. Wamiru M. K. Bona M. A. Parniak R. J. Crouch J. B. McMahon J. A. Beutler S. F. Le Grice Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones Nucleic Acids Res. 2005 33 1249 1256
39. D. M. Himmel K. A. Maegley T. A. Pauly J. D. Bauman K. Das C. Dharia A. D. Clark Jr. K. Ryan M. J. Hickey R. A. Love S. H. Hughes S. Bergqvist E. Arnold Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site Structure 2009 17 1625 1635
40. J. Q. Hang S. Rajendran Y. Yang Y. Li P. W. In H. Overton K. E. Parkes N. Cammack J. A. Martin K. Klumpp Activity of the isolated HIV RNase H domain and specific inhibition by N-hydroxyimides Biochem. Biophys. Res. Commun. 2004 317 321 329
41. V. Suchaud F. Bailly C. Lion E. Tramontano F. Esposito A. Corona F. Christ Z. Debyser P. Cotelle Development of a series of 3-hydroxyquinolin-2(1H)- ones as selective inhibitors of HIV-1 reverse transcriptase associated RNase H activity Bioorg. Med. Chem. Lett. 2012 22 3988 3992
42. M. Billamboz F. Bailly C. Lion N. Touati H. Vezin C. Calmels M. L. Andréola F. Christ Z. Debyser P. Cotelle Magnesium chelating 2-hydroxyisoquinoline-1,3(2H,4H)-diones, as inhibitors of HIV-1 integrase and/or the HIV-1 reverse transcriptase ribonuclease H domain: discovery of a novel selective inhibitor of the ribonuclease H function J. Med. Chem. 2011 54 1812 1824
43. T. A. Kirschberg M. Balakrishnan N. H. Squires T. Barnes K. M. Brendza X. Chen E. J. Eisenberg W. Jin N. Kutty S. Leavitt A. Liclican Q. Liu X. Liu J. Mak J. K. Perry M. Wang W. J. Watkins E. B. Lansdon RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information J. Med. Chem. 2009 52 5781 5784
44. E. B. Lansdon Q. Liu S. A. Leavitt M. Balakrishnan J. K. Perry C. Lancaster-Moyer N. Kutty X. Liu N. H. Squires W. J. Watkins T. A. Kirschberg Structural and binding analysis of pyrimidinol carboxylic acid and N-hydroxy quinazolinedione HIV-1 RNase H inhibitors Antimicrob. Agents Chemother. 2011 55 2905 2915
45. E. Tramontano F. Esposito R. Badas R. Di Santo R. Costi P. La Colla 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro Antiviral Res. 2005 65 117 124
46. C. A. Shaw-Reid V. Munshi P. Graham A. Wolfe M. Witmer R. Danzeisen D. B. Olsen S. S. Carroll M. Embrey J. S. Wai M. D. Miller J. L. Cole D. J. Hazuda Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino) thien-2-yl]-2,4-dioxobutanoic acid J. Biol. Chem. 2003 278 2777 2780
47. H. P. Su Y. Yan G. S. Prasad R. F. Smith C. L. Daniels P. D. Abeywickrema J. C. Reid H. M. Loughran M. Kornienko S. Sharma J. A. Grobler B. Xu V. Sardana T. J. Allison P. D. Williams P. L. Darke D. J. Hazuda S. Munshi Structural basis for the inhibition of RNaseH activity of HIV-1 Reverse Transcriptase by RNaseH active site-directed inhibitors J. Virol. 2010 84 7625 7633
48. P. D. Williams D. D. Staas S. Venkatraman H. M. Loughran R. D. Ruzek T. M. Booth T. A. Lyle J. S. Wai J. P. Vacca B. P. Feuston L. T. Ecto J. A. Flynn D. J. Distefano D. J. Hazuda C. M. Bahnck A. L. Himmelberger G. Dornadula R. C. Hrin K. A. Stillmock M. V. Witmer M. D. Miller J. A. Grobler Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin- 2(1H)-one scaffold Bioorg. Med. Chem. Lett. 2010 20 6754 6757
49. K. A. Kirby B. Marchand Y. T. Ong T. P. Ndongwe A. Hachiya E. Michailidis M. D. Leslie D. V. Sietsema T. L. Fetterly C. A. Dorst K. Singh Z. Wang M. A. Parniak S. G. Sarafianos Structural and inhibition studies of the RNase H function of xenotropic murine leukemia virus-related virus reverse transcriptase Antimicrob. Agents Chemother. 2012 56 2048 2061
50. H. Yanagita E. Urano K. Matsumoto R. Ichikawa Y. Takaesu M. Ogata T. Murakami H. Wu J. Chiba J. Komano T. Hoshino Structural and biochemical study on the inhibitory activity of derivatives of 5-nitro-furan-2-carboxylic acid for RNase H function of HIV-1 reverse transcriptase Bioorg. Med. Chem. 2011 19 816 825
51. H. Fuji E. Urano Y. Futahashi M. Hamatake J. Tatsumi T. Hoshino Y. Morikawa N. Yamamoto J. Komano Derivatives of 5-nitro-furan-2-carboxylic acid carbamoylmethyl ester inhibit RNase H activity associated with HIV-1 reverse transcriptase J. Med. Chem. 2009 52 1380 1387
52. M. Wendeler H. F. Lee A. Bermingham J. T. Miller O. Chertov M. K. Bona N. S. Baichoo M. Ehteshami J. Beutler B. R. O'Keefe M. Götte M. L. Kvaratskhelia S. Grice Vinylogous ureas as a novel class of inhibitors of reverse transcriptase-associated ribonuclease H activity ACS Chem. Biol. 2008 3 635 644
53. T. Masaoka S. Chung P. Caboni J. Rausch J. A. Wilson H. Taskent-Sezgin J. A. Beutler G. L. Tocco S. F. Grice Exploiting Drug-Resistant Enzymes as Tools to Identify Thienopyrimidinone Inhibitors of Human Immunodeficiency Virus Reverse Transcriptase-Associated Ribonuclease H J. Med. Chem. 2013 56 5436 5445
54. D. M. Himmel S. G. Sarafianos S. Dharmasena M. M. Hossain K. McCoy-Simandle T. Ilina A. D. Clark Jr. J. L. Knight J. G. Julias P. K. Clark K. Krogh-Jespersen R. M. Levy S. H. Hughes M. A. Parniak E. Arnold HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site ACS Chem. Biol. 2006 1 702 712
55. A. K. Felts K. Labarge J. D. Bauman D. V. Patel D. M. Himmel E. Arnold M. A. Parniak R. M. Levy Identification of alternative binding sites for inhibitors of HIV-1 ribonuclease H through comparative analysis of virtual enrichment studies J. Chem. Inf. Model. 2011 51 1986 1998
56. M. T. Christen L. Menon N. S. Myshakina J. Ahn M. A. Parniak R. Ishima Structural basis of the allosteric inhibitor interaction on the HIV-1 reverse transcriptase RNase H domain Chem. Biol. Drug Des. 2012 80 706 716
57. F. Esposito T. Kharlamova S. Distinto L. Zinzula Y. C. Cheng G. Dutschman G. Floris P. Markt A. Corona E. Tramontano Alizarine derivatives as new dual inhibitors of the HIV-1 reverse transcriptase-associated DNA polymerase and RNase H activities effective also on the RNase H activity of non-nucleoside resistant reverse transcriptases FEBS J. 2011 278 1444 1457
58. S. Distinto F. Esposito J. Kirchmair M. C. Cardia M. Gaspari E. Maccioni S. Alcaro P. Markt G. Wolber L. Zinzula E. Tramontano Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D fingerprint- and pharmacophore-based virtual screening approach Eur. J. Med. Chem. 2012 50 216 229
59. M. Gotte X. Li M. A. Wainberg HIV-1 reverse transcription: A brief overview focused on structure-function relationships among molecules involved in the initiation of the reaction Arch. Biochem. Biophys. 1999 365 199 210
60. M. Rigourd C. Ehresmann M. A. Parniak B. Ehresmann R. Marquet Primer unblocking and rescue of DNA synthesis by azidothymidine (AZT)-resistant HIV-1 reverse transcriptase J. Biol. Chem. 2002 277 18611 18618
61. J. D. Bauman D. Patel C. Dharia M. W. Fromer S. Ahmed Y. Frenkel R. S. Vijayan J. T. Eck W. C. Ho K. Das A. J. Shatkin E. Arnold Detecting Allosteric Sites of HIV-1 Reverse Transcriptase by X-ray Crystallographic Fragment Screening J. Med. Chem. 2013 56 2738 2746
62. X. Qiu Z. P. Liu Recent developments of peptidomimetic HIV-1 protease inhibitors Curr. Med. Chem. 2011 18 4513 4537
63. P. Cígler M. Kozísek P. Rezácová J. Brynda Z. Otwinowski J. Pokorná J. Plesek B. Grüner L. Dolecková- Maresová M. Mása J. Sedlácek J. Bodem H. G. Kräusslich V. Král J. Konvalinka From nonpeptide toward noncarbon protease inhibitors: metallacarboranes as specific and potent inhibitors of HIV protease Proc. Natl. Acad. Sci. U. S. A. 2005 102 15394 15399
64. M. Kozísek P. Cígler M. Lepsík J. Fanfrlík P. Rezácová J. Brynda J. Pokorná J. Plesek B. Grüner S. K. Grantz J. Václavíková V. Král J. Konvalinka Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance J. Med. Chem. 2008 51 4839 4843
65. P. Rezácová J. Pokorná J. Brynda M. Kozísek P. Cígler M. Lepsík J. Fanfrlík J. Rezác K. Grantz-Sasková I. Sieglová J. Plesek V. Sícha B. Grüner H. Oberwinkler J. Sedlácek' H. G. Kräusslich P. Hobza V. Král J. Konvalinka Design of HIV protease inhibitors based on inorganic polyhedral metallacarboranes J. Med. Chem. 2009 52 7132 7141
66. J. Schimer P. Cígler J. Veselý K. Grantz- ŠaŠková M. LepŠík J. Brynda P. Rezáčová M. KožíŠek I. Císařová H. Oberwinkler H. G. Kraeusslich J. Konvalinka Structure-aided design of novel inhibitors of HIV protease based on a benzodiazepine scaffold J. Med. Chem. 2012 55 10130 10135
67. T. Tiefenbrunn S. Forli M. M. Baksh M. W. Chang M. Happer Y. C. Lin A. L. Perryman J. K. Rhee B. E. Torbett A. J. Olson J. H. Elder M. G. Finn C. D. Stout Small Molecule Regulation of Protein Conformation by Binding in the Flap of HIV Protease ACS Chem. Biol. 2013 8 1223 1231
68. P. Zhan W. Li H. Chen X. Liu Targeting protein-protein interactions: a promising avenue of anti-HIV drug discovery Curr. Med. Chem. 2010 17 3393 3409
69. L. Dufau A. S. Marques-Ressurreição R. Fanelli N. Kihal A. Vidu T. Milcent J. L. Soulier-Rodrigo J. De-Losada A. Desvergne K. Leblanc G. Bernadat B. Crousse M. Reboud-Ravaux S. Ongeri Carbonylhydrazide-based molecular tongs inhibit wild-type and mutated HIV-1 protease dimerization J. Med. Chem. 2012 55 6762 6775
70. O. A. Flausino Jr. L. Dufau L. O. Regasini M. S. Petrônio D. H. Silva T. Rose V. S. Bolzani M. Reboud-Ravaux Alkyl hydroxybenzoic acid derivatives that inhibit HIV-1 protease dimerization Curr. Med. Chem. 2012 19 4534 4540
71. P. K. Quashie R. D. Sloan M. A. Wainberg Novel therapeutic strategies targeting HIV integrase BMC Med. 2012 10 34
72. T. Masuda Non-enzymatic functions of retroviral integrase: the next target for novel anti-HIV drug development Front. Microbiol. 2011 2 210
73. A. Engelman J. J. Kessl M. Kvaratskhelia Allosteric inhibition of HIV-1 integrase activity Curr. Opin. Chem. Biol. 2013 17 339 345
74. L. Q. Al-Mawsawi N. Neamati Allosteric inhibitor development targeting HIV-1 integrase ChemMedChem 2011 6 228 241
75. M. A. Walker New approaches for inhibiting HIV integrase: a journey beyond the active site Curr. Opin. Invest. Drugs (BioMed Cent.) 2009 10 129 136
76. L. Du Y. Zhao J. Chen L. Yang Y. Zheng Y. Tang X. Shen H. Jiang D77, one benzoic acid derivative, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75 Biochem. Biophys. Res. Commun. 2008 375 139 144
77. F. Christ A. Voet A. Marchand S. Nicolet B. A. Desimmie D. Marchand D. Bardiot N. J. Vander Veken B. Van Remoortel S. V. Strelkov M. De Maeyer P. Chaltin Z. Debyser Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication Nat. Chem. Biol. 2010 6 442 448
78. J. J. Kessl N. Jena Y. Koh H. Taskent-Sezgin A. Slaughter L. Feng S. de Silva L. Wu S. F. Le Grice A. Engelman J. R. Fuchs M. Kvaratskhelia Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors J. Biol. Chem. 2012 287 16801 16811
79. K. A. Jurado H. Wang A. Slaughter L. Feng J. J. Kessl Y. Koh W. Wang A. Ballandras-Colas P. A. Patel J. R. Fuchs M. Kvaratskhelia A. Engelman Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation Proc. Natl. Acad. Sci. U. S. A. 2013 110 8690 8695
80. C. Fenwick, R. Bethell, M. Cordingley, P. Edwards, A.-M. Quinson, P. Robinson, B. Simoneau and C. Yoakim, BI 224436, a non-catalytic site integrase inhibitor, is a potent inhibitor of the replication of treatment-naïve and raltegravir-resistant clinical isolates of HIV-1. In 51st Interscience Conference on Antimicrobials and Chemotherapy: 2011; Chicago, IL, USA; 2011. Levin: Conference Reports for NATAP; 2011, http://www.natap.org/2011/ICAAC/ ICAAC-34.htm
81. S. Aslanyan, C. H. Ballow, J. P. Sabo, J. Habeck, D. Roos, T. R. MacGregor, P. Robinson and J. Kort, Safety and pharmacokinetics (PK) of single rising oral doses of a novel HIV integrase inhibitor in healthy volunteers. In 51st Interscience Conference on Antimicrobials and Chemotherapy: 2011; Chicago, IL, USA; 2011. Levin: Conference Reports for NATAP; 2011, http://www.natap.org/ 2011/ICAAC/ICAAC-35.htm
82. F. Christ S. Shaw J. Demeulemeester B. A. Desimmie A. Marchand S. Butler W. Smets P. Chaltin M. Westby Z. Debyser C. Pickford Small-Molecule Inhibitors of the LEDGF/p75 Binding Site of Integrase Block HIV Replication and Modulate Integrase Multimerization Antimicrob. Agents Chemother. 2012 56 4365 4374
83. M. Tsiang G. S. Jones A. Niedziela-Majka E. Kan E. B. Lansdon W. Huang M. Hung D. Samuel N. Novikov Y. Xu M. Mitchell H. Guo K. Babaoglu X. Liu R. Geleziunas R. Sakowicz New Class of HIV-1 Integrase (IN) Inhibitors with a Dual Mode of Action J. Biol. Chem. 2012 287 21189 21203
84. P. Annapurna, L. Guo, G. Samuel, R. L. David, L. T. George and M. Nicholas, Inhibitors of human immunodeficiency virus replication, WO2012033735 A1, 2012
85. L. De Luca M. L. Barreca S. Ferro F. Christ N. Iraci R. Gitto A. M. Monforte Z. Debyser A. Chimirri Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75 ChemMedChem 2009 4 1311 1316
86. L. De Luca S. Ferro R. Gitto M. L. Barreca S. Agnello F. Christ Z. Debyser A. Chimirri Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor Bioorg. Med. Chem. 2010 18 7515 7521
87. L. De Luca R. Gitto F. Christ S. Ferro S. De Grazia F. Morreale Z. Debyser A. Chimirri 4-[1-(4-Fluorobenzyl)-4-hydroxy-1H-indol-3-yl]-2-hydroxy-4- oxobut-2-enoic acid as a prototype to develop dual inhibitors of HIV-1 integration process Antiviral Res. 2011 92 102 107
88. X. Fan F. H. Zhang R. I. Al-Safi L. F. Zeng Y. Shabaik B. Debnath T. W. Sanchez S. Odde N. Neamati Y. Q. Long Design of HIV-1 integrase inhibitors targeting the catalytic domain as well as its interaction with LEDGF/p75: A scaffold hopping approach using salicylate and catechol groups Bioorg. Med. Chem. 2011 19 4935 4952
89. G. Hu X. Li X. Zhang Y. Li L. Ma L. M. Yang G. Liu W. Li J. Huang X. Shen L. Hu Y. T. Zheng Y. Tang Discovery of inhibitors to block interactions of HIV-1 integrase with human LEDGF/p75 via structure-based virtual screening and bioassays J. Med. Chem. 2012 55 10108 10117
90. T. W. Sanchez B. Debnath F. Christ H. Z. Otake Debyser N. Neamati Discovery of novel inhibitors of LEDGF/p75-IN protein-protein interactions Bioorg. Med. Chem. 2013 21 957 963
91. E. Serrao B. Debnath H. Otake Y. Kuang F. Christ Z. Debyser N. Neamati Fragment-Based Discovery of 8-Hydroxyquinoline Inhibitors of the HIV-1 Integrase-Lens Epithelium-Derived Growth Factor/p75 (IN-LEDGF/p75) Interaction J. Med. Chem. 2013 56 2311 2322
92. A. M. Meehan D. T. Saenz J. Morrison C. Hu M. Peretz E. M. Poeschla LEDGF dominant interference proteins demonstrate prenuclear exposure of HIV-1 integrase and synergize with LEDGF depletion to destroy viral infectivity J. Virol. 2011 85 3570 3583
93. B. A. Desimmie M. Humbert E. Lescrinier J. Hendrix S. Vets R. Gijsbers R. M. Ruprecht U. Dietrich Z. Debyser F. Christ Phage Display-directed discovery of LEDGF/p75 binding cyclic peptide inhibitors of HIV replication Mol. Ther. 2012 20 2064 2075
94. Y. Q. Long S. X. Huang Z. Zawahir Z. L. Xu H. Li T. W. Sanchez Y. Zhi S. De Houwer F. Christ Z. Debyser N. Neamati Design of cell-permeable stapled peptides as HIV-1 integrase inhibitors J. Med. Chem. 2013 56 5601 5612
95. C. Tintori J. Demeulemeester L. Franchi S. Massa Z. Debyser F. Christ M. Botta Discovery of small molecule HIV-1 integrase dimerization inhibitors Bioorg. Med. Chem. Lett. 2012 22 3109 3114
96. J. Demeulemeester C. Tintori M. Botta Z. Debyser F. Christ Development of an AlphaScreen-based HIV-1 integrase dimerization assay for discovery of novel allosteric inhibitors J. Biomol. Screening 2012 17 618 628
97. L. Q. Al-Mawsawi V. Fikkert R. Dayam M. Witvrouw T. R. Burke Jr. C. H. Borchers N. Neamati Discovery of a small-molecule HIV-1 integrase inhibitor-binding site Proc. Natl. Acad. Sci. U. S. A. 2006 103 10080 10085
98. J. J. Kessl J. O. Eidahl N. Shkriabai Z. Zhao C. J. McKee S. Hess T. R. Burke Jr. M. Kvaratskhelia An allosteric mechanism for inhibiting HIV-1 integrase with a small molecule Mol. Pharmacol. 2009 76 824 832
99. J. Wielens S. J. Headey D. Jeevarajah D. I. Rhodes J. Deadman D. K. Chalmers M. J. Scanlon M. W. Parker Crystal structure of the HIV-1 integrase core domain complexed with sucrose reveals details of an allosteric inhibitory binding site FEBS Lett. 2010 584 1455 1462
100. D. I. Rhodes T. S. Peat N. Vandegraaff D. Jeevarajah G. Le E. D. Jones J. A. Smith J. A. Coates L. J. Winfield N. Thienthong J. Newman D. Lucent J. H. Ryan G. P. Savage C. L. Francis J. J. Deadman Structural basis for a new mechanism of inhibition of HIV-1 integrase identified by fragment screening and structure-based design Antiviral Chem. Chemother. 2011 21 155 168
101. L. Du Y. X. Zhao L. M. Yang Y. T. Zheng Y. Tang X. Shen H. L. Jiang Symmetrical 1-pyrrolidineacetamide showing anti-HIV activity through a new binding site on HIV-1 integrase Acta Pharmacol. Sin. 2008 29 1261 1267
102. A. Di Fenza W. Rocchia V. Tozzini Complexes of HIV-1 integrase with HAT proteins: multiscale models, dynamics, and hypotheses on allosteric sites of inhibition Proteins 2009 76 946 958
103. J. Wielens S. J. Headey J. J. Deadman D. I. Rhodes G. T. Le M. W. Parker D. K. Chalmers M. J. Scanlon Fragment-based design of ligands targeting a novel site on the integrase enzyme of human immunodeficiency virus 1 ChemMedChem 2011 6 258 261
104. P. Zhan X. Liu Rationally designed multitarget anti-HIV agents Curr. Med. Chem. 2013 20 1743 1758
105. P. Zhan X. Liu Designed multiple ligands: an emerging anti-HIV drug discovery paradigm Curr. Pharm. Des. 2009 15 1893 1917
106. Y. Song Z. Fang P. Zhan X. Liu Recent advances in the discovery and development of novel HIV-1 NNRTI platforms (Part II): 2009-2013 update Curr. Med. Chem. 2013 21 329 355
107. P. Zhan X. Liu Z. Li Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update Curr. Med. Chem. 2009 16 2876 2889
108. P. Zhan X. Chen D. Li Z. Fang E. De Clercq X. Liu HIV-1 NNRTIs: Structural diversity, pharmacophore similarity, and implications for drug design Med. Res. Rev. 2013 33 E1 E72
109. P. Zhan X. Liu Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005-2010) Expert Opin. Ther. Pat. 2011 21 717 796
110. P. Zhan X. Liu Z. Li C. Pannecouque E. De Clercq Design strategies of novel NNRTIs to overcome drug resistance Curr. Med. Chem. 2009 16 3903 3917
111. Z. Wang E. M. Bennett D. J. Wilson C. Salomon R. Vince Rationally designed dual inhibitors of HIV reverse transcriptase and integrase J. Med. Chem. 2007 50 3416 3419
112. Z. Wang J. Tang C. E. Salomon C. D. Dreis R. Vince Pharmacophore and structure-activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase Bioorg. Med. Chem. 2010 18 4202 4211
113. J. Tang K. Maddali C. D. Dreis Y. Y. Sham R. Vince Y. Pommier Z. Wang N-3 Hydroxylation of pyrimidine-2,4-diones yields dual inhibitors of HIV reverse transcriptase and integrase ACS Med. Chem. Lett. 2011 2 63 67
114. J. Tang K. Maddali M. Metifiot Y. Y. Sham R. Vince Y. Pommier Z. Wang 3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integrase J. Med. Chem. 2011 54 2282 2292
115. J. Tang K. Maddali C. D. Dreis Y. Y. Sham R. Vince Y. Pommier Z. Wang 6-Benzoyl-3-hydroxypyrimidine-2,4-diones as dual inhibitors of HIV reverse transcriptase and integrase Bioorg. Med. Chem. Lett. 2011 21 2400 2402
116. Y. Song P. Zhan X. Li D. Rai E. De Clercq X. Liu Multivalent agents: a novel concept and preliminary practice in Anti-HIV drug discovery Curr. Med. Chem. 2013 20 815 832
117. C. M. Bailey T. J. Sullivan P. Iyidogan J. Tirado-Rives R. Chung J. Ruiz-Caro E. Mohamed W. Jorgensen R. Hunter K. S. Anderson Bifunctional inhibition of human immunodeficiency virus type 1 reverse transcriptase: mechanism and proof-of-concept as a novel therapeutic design strategy J. Med. Chem. 2013 56 3959 3968
118. X. Hu R. Manetsch Kinetic target-guided synthesis Chem. Soc. Rev. 2010 39 1316 1324
119. P. Thirumurugan D. Matosiuk K. Jozwiak Click chemistry for drug development and diverse chemical-biology applications Chem. Rev. 2013 113 4905 4979
120. M. Whiting J. Muldoon Y. C. Lin S. M. Silverman W. Lindstrom A. J. Olson H. C. Kolb M. G. Finn K. B. Sharpless J. H. Elder V. V. Fokin Inhibitors of HIV-1 protease by using in situ click chemistry Angew. Chem., Int. Ed. 2006 45 1435 1439
121. A. Brik J. Muldoon Y. C. Lin J. H. Elder D. S. Goodsell A. J. Olson V. V. Fokin K. B. Sharpless C. H. Wong Rapid diversity-oriented synthesis in microtiter plates for in situ screening of HIV protease inhibitors ChemBioChem 2003 4 1246 1248
122. J. Wannberg N. F. Kaiser L. Vrang B. Samuelsson M. Larhed A. Hallberg High-speed synthesis of potent C2-symmetric HIV-1 protease inhibitors by in situ aminocarbonylations J. Comb. Chem. 2005 7 611 617
123. A. L. Hopkins C. R. Groom A. Alex Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004 9 430 431
124. C. E. Mowbray C. Burt R. Corbau M. Perros I. Tran P. A. Stupple R. Webster A. Wood Pyrazole NNRTIs 1: design and initial optimisation of a novel template Bioorg. Med. Chem. Lett. 2009 19 5599 5602
125. C. E. Mowbray R. Corbau M. Hawes L. H. Jones J. E. Mills M. Perros M. D. Selby P. A. Stupple R. Webster A. Wood Pyrazole NNRTIs 3: optimisation of physicochemical properties Bioorg. Med. Chem. Lett. 2009 19 5603 5606
126. C. E. Mowbray C. Burt R. Corbau S. Gayton M. Hawes M. Perros I. Tran D. A. Price F. J. Quinton M. D. Selby P. A. Stupple R. Webster A. Wood Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate Bioorg. Med. Chem. Lett. 2009 19 5857 5860
127. G. Fätkenheuer S. Staszewski A. Plettenburg F. Hackman G. Layton L. McFadyen J. Davis T. M. Jenkins Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients AIDS 2009 23 2115 2122
128. R. Corbau J. Mori C. Phillips L. Fishburn A. Martin C. Mowbray W. Panton C. Smith-Burchnell A. Thornberry H. Ringrose T. Knöchel S. Irving M. Westby A. Wood M. Perros Lersivirine: a non-nucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus-1 Antimicrob. Agents Chemother. 2010 54 4451 4463
129. A. T. García-Sosa S. Sild K. Takkis U. Maran Combined approach using ligand efficiency, cross-docking, and antitarget hits for wild-type and drug-resistant Y181C HIV-1 reverse transcriptase J. Chem. Inf. Model. 2011 51 2595 2611
130. L. H. Jones G. Allan O. Barba C. Burt R. Corbau T. Dupont T. Knöchel S. Irving D. S. Middleton C. E. Mowbray M. Perros H. Ringrose N. A. Swain R. Webster M. Westby C. Phillips Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays J. Med. Chem. 2009 52 1219 1223
131. Y. Tanaka K. Aikawa G. Nishida M. Homma S. Sogabe S. Igaki Y. Hayano T. Sameshima I. Miyahisa T. Kawamoto M. Tawada Y. Imai M. Inazuka N. Cho Y. Imaeda T. Ishikawa Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins J. Med. Chem. 2013 56 9635 9645
132. J. E. Dowling C. Chuaqui T. W. Pontz P. D. Lyne N. A. Larsen M. H. Block H. Chen N. Su A. Wu D. Russell H. Pollard J. W. Lee B. Peng K. Thakur Q. Ye T. Zhang P. Brassil V. Racicot L. Bao C. R. Denz E. Cooke Potent and selective inhibitors of CK2 kinase identified through structure-guided hybridization ACS Med. Chem. Lett. 2012 3 278 283
133. H. Huang A. Guzman-Perez L. Acquaviva V. Berry H. Bregman J. Dovey H. Gunaydin X. Huang L. Huang D. Saffran R. Serafino S. Schneider C. Wilson E. F. DiMauro Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitors ACS Med. Chem. Lett. 2013 4 1218 1223
134. H. Bregman N. Chakka A. Guzman-Perez H. Gunaydin Y. Gu X. Huang V. Berry J. Liu Y. Teffera L. Huang B. Egge E. L. Mullady S. Schneider P. S. Andrews A. Mishra J. Newcomb R. Serafino C. A. Strathdee S. M. Turci C. Wilson E. F. DiMauro Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors J. Med. Chem. 2013 56 4320 4342
135. Y. Song W. Chen D. Kang Q. Zhang P. Zhan X. Liu "Old friends in new guise": exploiting privileged structures for scaffold re-evolution/refining Comb. Chem. High Throughput Screening 2014 10.2174/1386207317666140122101631
136. J. D. Bauman D. Patel E. Arnold Fragment screening and HIV therapeutics Top. Curr. Chem. 2012 317 181 200
137. M. Hennig A. Ruf W. Huber Combining biophysical screening and X-ray crystallography for fragment-based drug discovery Top. Curr. Chem. 2012 317 115 143